DrugPatentWatch Database Preview
Litigation Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)
Email this page to a colleague
» See Plans and PricingBiogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)
| Docket | Start Trial | Date Filed | 2017-06-30 |
| Court | District Court, N.D. West Virginia | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Irene Patricia Murphy Keeley |
| Jury Demand | None | Referred To | James P. Mazzone |
| Parties | BIOGEN INTERNATIONAL GMBH; BIOGEN MA, INC.; MYLAN PHARMACEUTICALS INC. | ||
| Patents | 10,029,015; 6,509,376; 6,926,907; 7,320,999; 8,013,002; 8,399,514; 8,759,393; 9,018,017; 9,024,096 | ||
| Attorneys | Aaron G. Clay; Adam S Ennis; Andrew E. Renison; Brandon M. White; Courtney M. Prochnow; David L. Anstaett; Emily J. Greb; Eric J. Fues; Gordon H. Copland; James B. Monroe; James F. Companion; Jeanette M. Roorda; John E. Nappi; Laura P Masurovsky; Lauren J. Dowty; Li Feng; Michael A. Chajon; Paul W. Browning; Sanya Sukduang; Shannon M Bloodworth; Travis L. Zeik; William J O'Brien | ||
| Firms | Finnegan Henderson Farabow Garrett and Dunner; Perkins Coie LLC; Perkins Coie LLP; Perkins Coie, LLP; Schrader Companion Duff & Law, PLLC; Steptoe & Johnson PLLC - Bridgeport; Steptoe & Johnson PLLC, Cannonsburg | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.
The small molecule drugs covered by the patents cited in this case are Start Trial , Start Trial , Start Trial , and Start Trial .
Biologic Drugs cited in Biogen International GMBH v. Mylan Pharmaceuticals Inc.
The biologic drugs covered by the patents cited in this case are Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , and Start Trial .
Details for Biogen International GMBH v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-06-30 | 1 | Complaint | 393 patent”) and 8,399,514 (“the ‘514 patent”) arising under the patent laws of the United States, Title…- 376 Patent, # 2 Exhibit B - 999 Patent, # 3 Exhibit C - 001 Patent, # 4 Exhibit D - 840 Patent, # 5 …is an action for patent infringement of U.S. Patent Nos. 6,509,376 (“the ‘376 patent”), 7,320,999 (“the…“the ‘999 patent”), 7,619,001 (“the ‘001 patent”), 7,803,840 (“the ‘840 patent”), 8,759,393 (“the ‘393…5 Exhibit E - 393 Patent, # 6 Exhibit F - 514 Patent, # 7 Civil Cover Sheet)(lmm) (Entered: 06/30/2017 | External link to document |
| 2018-10-12 | 142 | Status Report | infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), 7,619,001 … (“the ’001 patent”), 7,803,840 (“the ’840 patent”), 8,759,393 (“the ’393 patent”) and 8,399,514 … the patents-in-suit. The ’393 patent has expired. It is Mylan’s position that this patent should be…partes review (“IPR”) of Biogen’s ’514 patent. Biogen’s Patent Owner’s Preliminary Response is due on…for regulatory patent term extension (“PTE”) on the ’376, ’999, ’001, and ’840 patents. Under the relevant | External link to document |
| 2019-02-05 | 196 | Stipulation and Order | affirmative defenses related to U.S. Patent Nos. 6,509,376; 7,320,999; 7,803,840; and 8,759,393. The parties…counterclaims and affirmative defenses as to U.S. Patent Nos. 7,619,001 and 8,399,514. Signed by Senior … 30 June 2017 1:17-cv-00116 835 Patent - Abbreviated New Drug Applications (ANDA) | External link to document |
| 2019-10-08 | 288 | Order | Parties to this patent infringement case involving U.S. Patent Nos. 8,399,514 (“the °514 patent”) and 7,619,001… 15-16 of the °514 patent and claims 1-3, 6-9, 12-19, and 22-24 of the *001 patent under 35 U.S.C. § 271…and 15-16 of the 514 patent and claims 1-3, 6-9, 12-19, and 22-24 of the °001 patent are not invalid and…7,619,001 (‘the 001 patent”); WHEREAS the Parties wish to narrow the issues in this litigation; WHEREAS…that it will not assert claims 17-19 of the 514 patent against Mylan (see ECF 102); THEREFORE, IT IS | External link to document |
| 2020-01-03 | 299 | Notice (Other) | Rajendra Kumar Joshi; Hans- 6,509,376 1/21/03 United…invalidate U.S. Patent Nos. 7,619,001 (“the ’001 patent”) and 8,399, 514 (“the ’514 patent”) (collectively… the “patents-in-suit”) and/or show the state of the art relative to the asserted patents. … Patents and File Histories Date of Issue/ Patent/Patent… Date of Issue/ Patent/Patent Publication Country of Publication | External link to document |
| 2020-01-09 | 308 | Other Document | 13:23-14:12 21:15-17 22:10-14 28:10-29:15 29:19-23 30:13-18 30:20-31:19 …June 2017 22 June 2020 1:17-cv-00116 Patent - Abbreviated New Drug Applications (ANDA) | External link to document |
| 2020-01-16 | 323 | Other Document | asserted claims of United States Patent No. 8,399,514 (“the ’514 patent”), on issues including invalidity…invalidity of the asserted claims of the ’514 patent, on issues including the lack of any secondary …invalidity of the asserted claims of the ’514 patent, including the lack of any secondary considerations…United States International Trade Commission, the Patent Trial and Appeal Board, and on matters before various…Hofmann has also been engaged by the United States Patent and Trademark Case 1:17-cv-00116-IMK-JPM Document | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
